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Introduction
Monoclonal antibodies (mAbs) developed as human therapeutics 
have had substantial success as measured by global sales of mar-
keted pharmaceuticals in recent years because of their exquisite 
specificity toward a variety of targets and often limited side effects. 
This success has led to rapid technological advancements that have 
enabled the discovery and optimization of potent mAb therapeu-
tic candidates, using strategies ranging from transgenic mice to 
phage and other display selection methods.1 MAbs are complex 
proteins typically produced in mammalian cell cultures through 
elaborate manufacturing process designed to yield consistent prod-
ucts. The molecular properties of the mAbs, such as solubility, 
production yields in certain cell lines, and resistance to chemical 
modifications, play an essential role in the success of the manufac-
turing process. As the use of mAbs for chronic disease indications 
becomes more common, their amenability to convenient delivery 
methods such as subcutaneous injection has become increasingly 
important. Subcutaneous delivery requires a small volume (pre-
ferred at <1.5 mL) of a high doses (>10 mg/kg),2 thus requiring 
high concentration formulations. As a result, highly soluble mAbs 
have become a subject of intense research in recent years.3-10
the successful development of antibody therapeutics depends on the molecules having properties that are suitable 
for manufacturing, as well as use by patients. Because high solubility is a desirable property for antibodies, screening 
for solubility has become an essential step during the early candidate selection process. In considering the screening 
process, we formed a hypothesis that hybridoma antibodies are filtered by nature to possess high solubility and tested this 
hypothesis using a large number of murine hybridoma-derived antibodies. Using the cross-interaction chromatography 
(CIC) method, we screened the solubility of 92 murine hybridoma-derived monoclonal antibodies and found that all of 
these molecules exhibited CIC profiles that are indicative of high solubility (>100 mg/mL). Further investigations revealed 
that variable region N-linked glycosylation or isoelectric parameters are unlikely to contribute to the high solubility of 
these antibodies. these results support the general hypothesis that hybridoma monoclonal antibodies are highly soluble.
Solubility evaluation of murine hybridoma 
antibodies
Stacey Spencer,† Deidra Bethea,† t. Shantha Raju, Jill Giles-Komar and Yiqing Feng*
Biotechnology Center of excellence; Janssen Research & Development, LLC; Radnor, pA USA
†these authors contributed equally to this work.
Keywords: monoclonal antibody, immunoglobulin, hybridoma, solubility, cross-interaction chromatography, glycosylation, 
isoelectric point
Abbreviations: mAb, monoclonal antibody; SEC, size exclusion chromatography; CIC, cross-interaction chromatography; DLS, 
dynamic light scattering; IgG, immunoglobulin G; Fc, constant domain; Fv, variable domain; Fab, antigen binding fragment; 
V-region, variable region; MALDI-TOF-MS, matrix assisted laser desorption ionization-time of flight-mass spectrometry;  
IEF, isoelectric focusing
Human therapeutic mAbs are commonly generated using 
either display methods, including the selection of humanized and 
affinity-matured murine antibodies, or from transgenic animals. 
Engineering efforts to improve the solubility of highly potent 
mAbs have been reported recently in reference 11 and 12. In 
these cases, mAbs with poor solubility were derived using phage 
display selection methods. Our recent experience in screening 
the solubility of phage-derived mAbs suggests that the solubility 
screen is a crucial step to eliminate less soluble mAbs early in the 
process. We began to ask the question whether a solubility screen 
would be equally crucial for mAbs generated directly from ani-
mals. Due to the lack of access to a large number of human mAbs 
from human or transgenic animal sources, we investigated the 
solubility properties of murine hybridoma-derived mAbs.
Cross-interaction chromatography (CIC) has emerged as a 
simple and efficient screening tool to select highly soluble human 
mAbs.10 This method measures weak protein-protein interactions 
between a target human mAb in solution phase and human poly-
clonal antibodies immobilized to a resin matrix, and identifies 
mAbs that have high solubility (>100 mg/mL). We have adapted 
this method to screen the solubility of murine hybridoma-derived 
antibodies by immobilizing murine polyclonal antibodies to the 
resin matrix. We evaluated the solubility of 92 murine hybridoma ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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proteins. The CIC data showed that all 92 hybridoma-derived 
mAbs yielded k' value of < 0.2, suggesting that they are highly likely 
to reach concentrations above 100 mg/mL at neutral pH (represen-
tative data shown in Figure 1; data summarized in Table 1).
Aggregation assessment by dynamic light scattering (DLS) 
method. To further assess the solution property of these mAbs, 
we performed DLS experiments on a randomly selected set of 14 
mAbs. All these mAbs were found to have hydrodynamic radii 
and polydispersity that indicate predominantly monomer (Table 
2). The DLS results are consistent with the above SEC and CIC 
results.
The potential effect of variable region N-linked glycosyl-
ation. Although all the mAbs used in this study showed highly 
soluble CIC profiles, it is possible that some of these antibodies 
rely on additional N-linked glycosylation moieties in the variable 
region to maintain high solubility. Our laboratory, as well as oth-
ers, has experienced situations in which antibodies with low solu-
bility became highly soluble upon the addition of an N-linked 
glycosylation moiety in the variable domain.11,12
The consensus N-linked glycosylation site consists of a three-
residue motif Asn-X-Ser/Thr, where X can be any amino acid 
residue except Pro.13,14 Five of the 92 murine hybridoma anti-
bodes in this study have sequences available that do not contain 
any consensus N-linked glycosylation site in their V-regions, 
while the remaining 87 mAbs were not sequenced. To investi-
gate whether a significant number of these 87 antibodies have 
additional N-linked glycosylation moiety that may enhance their 
solubility, we performed enzymatic deglycosylation experiments 
on 63 of the 87 hybridoma antibodies and assessed their molecu-
lar weight changes by MALDI-TOF-MS. The MALDI-TOF-MS 
mAbs by the CIC method and found that all antibodies in this 
study exhibited high solubility profile. These results are consistent 
with the SEC and DLS measurements. In addition, we investigated 
the potential contribution from either variable region (V-region) 
N-linked gylcosylation or isoelectric points (pI) that could have 
enhanced the solubility at neutral pH. We found that the high 
solubility profiles of the antibodies unlikely assisted by either 
V-region N-linked gylcosylation or extreme isoelectric points. 
These findings support the hypothesis that hybridoma antibodies 
are more likely to be highly soluble, meeting one of the important 
requirements for a successful therapeutic mAb development.
Results
Aggregation assessment by size exclusion chromatography (SEC) 
method. We first evaluated the presence of aggregation in the 92 
hybridoma-derived murine antibodies by the SEC-HPLC method. 
All the antibodies were found to be >94% monomeric.
Solubility screen by the CIC method. The CIC solubility 
screen using polyclonal human IgG has been established previously 
as a high-throughput method to screen for the solubility of human 
mAbs.10 It was shown that highly soluble antibodies have chromato-
graphic retention factor (k') values near zero. Antibodies with k' 
values > 0.6 are generally significantly less soluble.
This underlying principle is applicable to antibodies derived 
from other species. We modified this method to test hybridoma 
antibodies generated in mice by immobilizing polyclonal murine 
IgG to a column. Using this method, we evaluated the solubility of 
92 hybridoma-derived murine antibodies. These hybridoma anti-
bodies were raised against more than 20 different soluble antigenic 
Figure 1. Representative murine hybridoma antibody CIC profiles on murine polyclonal IgG coupled column. peak height differences are due to injec-
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D o   n o t   d i s t r i b u t e .
www.landesbioscience.com mAbs  321
method has been successfully used to monitor enzymatic degly-
cosylation of antibodies.15
The mAbs showing intact molecular weight higher than 148 
kDa typically contain additional glycosylation in the V-region, 
while those under ~148 kDa contain only Fc glycosylation.15 
Representative MALDI-TOF-MS spectra of two murine anti-
bodies (mAb 3 and mAb 17), before and after treatment with 
PNGase F, are shown in Figure 2. The majority of the 63 mAbs 
had molecular weights in the vicinity of 148 kDa and were found 
to be glycosylated in the Fc region only, where a ~2.5–3 kDa 
decrease in molecular weight (m/z of +1 ion) was observed upon 
deglycosylation (Fig. 2A and B). Eleven antibodies were identi-
fied as potentially having N-linked oligosaccharide in the vari-
able domain, exhibiting intact mass significantly above 148 kDa 
(e.g., Fig. 2C) and a mass loss of more than ~3 kDa upon the 
enzymatic treatment (e.g., Fig. 2D). MAb 3 (in Fig. 2C and D) 
seems to contain a mixture of IgGs with 3 or 4 N-linked glycans 
of which a large majority of molecules seems to contain at least 
3 glycans. The CIC profiles of the 11 antibodies before and after 
the non-denaturing PNGase F treatment were compared. The 
profiles and the k' values before and after the treatment are simi-
lar (Table 1), suggesting that no significant changes in solubility 
occurred upon the removal of the N-linked oligosaccharides in 
the V-region.
The effect of isoelectric point (pI) on solubility. The isoelec-
tric point (pI) of a protein is defined as the pH where a protein 
is charge-neutral and intramolecular electrostatic repulsion is at 
its lowest. Therefore, proteins are typically least soluble at their 
pI.16 As the solubility of proteins can be significantly improved 
in pH ranges far from their pI, we investigated the possibility 
that our antibodies are highly soluble in the PBS buffer because 
they carry a large amount of charges at neutral pH. The pI val-
ues for 50 hybridoma mAbs randomly selected from the panel 
of 92 mAbs were determined by isoelectric focusing (listed in 
Table 1). We found that for all mAbs measured, the pIs fell in 
the range of 5.5–8.3, with the majority of them (~90%) within 
6–8. Therefore, the charges of the mAbs under investigation are 
unlikely to aid the high solubility profiles at neutral pH.
Discussions
Development of antibody therapeutics is a complex process that 
involves the expression and purification of the antibodies from 
mammalian cell cultures and formulation in stabilizing buffers 
that minimize aggregation and chemical degradation over a long 
period of time. The molecular properties of the antibodies pro-
foundly affect the efficiency of the process. For high concentra-
tion formulations, the solubility of the antibodies is one of the 
most important properties that determine the success.
We have found that screening for solubility is a very impor-
tant step in the selection of phage-derived therapeutic antibodies. 
Hybridoma antibodies have been hypothesized as being filtered 
by nature and thus more likely to be highly soluble compared with 
antibodies that are selected using display selection methods. We 
examined this hypothesis by evaluating the solubility of a large 
number of murine hybridoma antibodies using a modified CIC 
Table 1. Retention factor k’ and pI of murine mAb derived  
from hybridoma1
mAb # k’2 k’ after deglycosylation pI
1 0.01 ± 0.02 7.2
2 0.00 0.03 7.2
3 -0.02 ± 0.04 0.00 N.D.
4 0.02 7.1
5 0.01 ± 0.01 7.1
6 0.00 7.3
7 0.02 N.D.
8 0.00 N.D.
9 0.00 ± 0.00 7.7
10 0.00 7.3
11 0.01 ± 0.03 N.D.
12 0.01 ± 0.01 7.2
13 0.02 ± 0.04 5.9
14 0.01 ± 0.02 7.0
15 0.01 ± 0.01 N.D.
16 0.00 N.D.
17 0.03 ± 0.01 8.3
18 0.18 6.5
19 -0.01 ± 0.06 N.D.
20 0.04 N.D.
21 0.01 ± 0.01 7.2
22 0.11 ± 0.15 0.05 7.2
23 0.03 ± 0.01 7.3
24 0.09 7.0
25 0.02 ± 0.01 7.4
26 0.16 0.13 N.D.
27 0.01 ± 0.00 7.0
28 0.09 N.D.
29 0.13 0.15 6.9
30 0.00 N.D.
31 0.00 N.D.
32 0.00 N.D.
33 0.05 ± 0.01 0.06 6.9
34 0.09 N.D.
35 0.04 0.05 N.D.
36 0.01 ± 0.03 7.2
37 0.00 8.0
38 0.07 N.D.
39 0.00 ± 0.00 N.D.
40 0.02 ± 0.01 6.9
41 0.04 N.D.
42 0.06 ± 0.03 7.0
1Samples with italic and bold numbers were not subjected to MALDI-
toF-MS analysis; Samples 89–92 have V-region sequences available and 
do not contain consensus N-linked glycosylation site; for the antibodies 
identified to contain V-region glycosylation, the retention factors (k’) 
upon deglycosylation are listed. 2the errors are calculated from n = 2 
chromatographic experiments.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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method. The CIC method, with human polyclonal IgG coupled 
to the column matrix, has been previously established as a high-
throughput solubility screening method for human therapeutic 
mAbs.10 The retention factor k' is used to describe the interaction 
between the antibodies in the stationary phase and the antibody in 
the solution phase. We have replaced human polyclonal IgG with 
murine polyconal IgG on the column to screen for the solubility 
of murine hybridoma mAbs. Our evaluation of 92 murine hybrid-
oma-derived mAbs showed that all of them exhibited high solubil-
ity profiles with k' < 0.2. The SEC data on all the mAbs and the 
DLS data on a selected set of mAbs indicate the lack of significant 
aggregation in these mAb solutions.
We further explored alternative reasons to account for the 
results. Low solubility, or the tendency to aggregate at relatively 
low concentrations, is thought to be due to the presence of spe-
cific hydrophobic sequence motifs that are prone to participating 
in intermolecular interactions.17 While nature may have selected 
antibody sequences that are devoid of such aggregation-prone 
hydrophobic motifs, it may have employed other means to make 
antibodies highly soluble. One of such possibilities is having addi-
tional glycosylation in the V-region to shield the hydrophobic 
motifs. Such glycosylation are likely N-linked glycan since O-linked 
glycosylation is rare for antibodies.18 All antibodies generated from 
mammalian sources have N-linked oligosaccharides attached to 
Asn297 in the Fc region, which are somewhat buried and affect 
the conformation of the CH2 domain along with the effector func-
tions.18-20 A significant percentage of natural antibodies is known to 
have glycosylation in the variable region. Approximately 18% of the 
heavy chain variable region sequences in the Kabat database con-
tain a consensus N-linked glycosylation site. Experimentally, about 
15–25% of the Fab fragments and 15% of the light chains isolated 
from human myeloma proteins were found to contain N-linked oli-
gosaccharides.21 The additional N-linked glycosylation may play an 
important role in solubility in addition to affinity, specificity, half-
life and immunogenicity.22-24 We found in a previous study that the 
addition of an N-linked oligosaccharide in the V-region dramati-
cally altered the solubility of an antibody.11 A similar improvement 
in solubility was reported by Pepinsky et al. when new N-linked 
glycosylation sites were introduced to the CH1 domain of an anti-
body with poor solubility.12
In this case, we found that ~17% of the antibodies studied by 
MALDI-TOF-MS have additional N-linked glycosylation in the 
V-region, consistent with the previously reported percentage. The 
CIC profiles of these mAbs did not change upon deglycosylation, 
which suggests that the presence of the glycans does not affect their 
solubility. Based on this data, we conclude that the antibodies in 
our study unlikely rely on additional N-linked glycosylation to 
achieve high solubility.
Antibody solubility is highly dependent on solution conditions 
such as pH, salt and other excipients. The hybridoma antibod-
ies could have extremely low or high pIs to render them highly 
charged and thus highly soluble due to charge repulsion in the 
functional pH range. However, we found that ~90% of the mAbs 
that we measured have pIs in a relatively narrow range of 6–8, 
while all the mAbs that we measured have pIs between 5.5 and 8.3. 
This data makes charge repulsion an unlikely contributor to the 
Table 1. Retention factor k’ and pI of murine mAb derived  
from hybridoma1
mAb # k’2 k’ after deglycosylation pI
43 0.00 ± 0.03 N.D.
44 0.05 N.D.
45 0.00 7.4
46 0.00 ± 0.00 7.4
47 0.12 ± 0.02 7.7
48 0.00 7.2
49 0.09 ± 0.01 7.3
50 0.04 N.D.
51 0.04 ± 0.01 7.6
52 0.04 ± 0.00 6.9
53 0.03 ± 0.01 0.00 N.D.
54 0.16 N.D.
55 0.00 ± 0.04 7.1
56 0.04 N.D.
57 0.04 ± 0.01 7.4
58 0.03 N.D.
59 0.01 7.3
60 0.01 ± 0.01 N.D.
61 0.06 ± 0.01 N.D.
62 0.06 ± 0.01 7.6
63 0.07 ± 0.10 7.6
64 0.06 N.D.
65 0.00 7.7
66 0.04 ± 0.06 6.9
67 0.03 ± 0.04 0.11 5.8
68 0.02 ± 0.03 7.0
69 0.04 N.D.
70 0.08 N.D.
71 0.02 ± 0.03 0.05 7.8
72 0.12 N.D.
73 0.03 N.D.
74 0.03 N.D.
75 0.01 7.0
76 0.03 ± 0.04 8.3
77 0.07 N.D.
78 0.13 N.D.
79 0.03 7.2
80 0.04 6.9
81 0.07 N.D.
82 0.02 ± 0.02 N.D.
83 0.05 N.D.
84 0.04 N.D.
1Samples with italic and bold numbers were not subjected to MALDI-
toF-MS analysis; Samples 89–92 have V-region sequences available and 
do not contain consensus N-linked glycosylation site; for the antibodies 
identified to contain V-region glycosylation, the retention factors (k’) 
upon deglycosylation are listed. 2the errors are calculated from n = 2 
chromatographic experiments.
(continued)©2 0 1 1   L a n d e s   B i o s c i e n c e .
D o   n o t   d i s t r i b u t e .
www.landesbioscience.com mAbs  323
in PBS buffer (Gibco, 14190-136) with measurements taken at 
215 nm and 280 nm wavelengths.
Cross-interaction chromatography (CIC) method. Murine 
polyclonal antibodies purified from pooled mouse serum were 
purchased from Sigma-Aldrich (I5381). Murine polyclonal anti-
bodies were coupled to the resin matrix at ~30 mg/mL using the 
protocol described by Jacobs et al. Purified murine hybridoma 
mAbs in PBS buffer were injected to the murine IgG-coupled 
column and the control column, respectively, with concentra-
tions range from 0.05 to 0.20 mg/mL. The retention times 
were used to calculate the retention factor k' values reported in   
Table 1.29
Vr represents the elution volume of the sample on the protein 
coupled column, Vo the elution volume from a control column, 
Tr the retention time on the protein coupled column, and Tm 
the retention time on the control column. A number of samples 
were run twice on the same column.
high solubility. This observed pI range is in agreement with previ-
ous reports on the pI of hybridoma mAbs against a variety of anti-
gens (reviewed in refs. 25 and 26).
None of the 92 randomly selected murine hybridoma antibodies 
in this study exhibited a low solubility CIC profile. This is in sharp 
contrast to our experiences with screening a large number of human 
antibodies selected from phage display experiments, where we have 
observed a higher incidence of mAbs with low solubility as indi-
cated by their CIC profiles (unpublished data). For some targets, 
we found that more than 30% of the mAbs selected from phage 
libraries exhibited low solubility CIC profile. A direct comparison 
was not attempted in this report because the antibodies were against 
different antigens. A comparison of antibodies derived from phage 
display selection method and hybridoma method against the same 
target is the subject of future investigations.
The results from this study provide an anecdotal support to the 
hypothesis that hybridoma antibodies are more likely to be highly 
soluble. Our experiences are that, with the additional scrutiny for 
solubility in place, all antibody generation methods can lead to 
highly potent, as well as highly soluble, antibodies for therapeu-
tic applications. It is also important to note that high solubility is 
just one of the desirable properties of therapeutic antibodies, and it 
alone does not guarantee the success of the complex development 
process involving expression, purification and formulation.27,28
Materials and Methods
Source of murine hybridoma antibodies. The hybridoma anti-
bodies used in this study were obtained by immunizing Balb/c 
mice with >20 different soluble proteins. Mice that demonstrated 
positive serum titers for the antigens were selected for hybridoma 
fusion. Splenocytes, which contain antibody-producing B cells 
from titer positive mice, were fused with an immortal cell line and 
the resulting hydridoma cells were cultured under selection condi-
tions that allowed only hybridoma cells to grow. Growth-positive 
hybridomas secreting antigen-specific antibodies were selected for 
limited dilution subcloning. Binding assays were utilized to select 
antibodies that bound to the respective antigens specifically. While 
the majority of the 92 murine antibodies are in subclass IgG1, the 
rest are divided in subclasses IgG2a and IgG2b.
For most of the antibodies, a two-step pH elution purification 
process with protein G was used. The first step used was with 250 
mM citrate buffer pH 4.5 while the second step employed was with 
100 mM glycine buffer at pH 2.5. Most of the mAbs were eluted at 
pH 2.5 step. Some of the antibodies used in this study were purified 
using either MabSelect with one step elution using 0.1 M sodium 
citrate pH 3.0, or MabSuRe with one step elution using 0.1 M 
sodium acetate pH 3.5. Regardless of the capturing method, the 
eluted fractions were neutralized with 10% the elution volume of 
1 M TRIS-HCl pH 8.0 and dialyzed into PBS buffer. The purity 
of the antibodies was assessed by SDS-PAGE gel electrophoresis to 
be >95%.
Size exclusion chromatography. The quality of the antibod-
ies was further assessed using SEC-HPLC chromatography. 
Approximately 20 ml of each sample (1–2 mg/mL) was loaded 
onto a Tosoh TSKgel G3000Wx1 column and eluted for 20 min 
Table 1. Retention factor k’ and pI of murine mAb derived  
from hybridoma1
mAb # k’2 k’ after deglycosylation pI
85 0.03 6.6
86 0.04 N.D.
87 0.05 ± 0.04 0.00 N.D.
88 -0.02 N.D.
89 0.09 6.9
90 0.01 5.5
91 -0.01 6.2
92 -0.03 5.5
1Samples with italic and bold numbers were not subjected to MALDI-
toF-MS analysis; Samples 89–92 have V-region sequences available and 
do not contain consensus N-linked glycosylation site; for the antibodies 
identified to contain V-region glycosylation, the retention factors (k’) 
upon deglycosylation are listed. 2the errors are calculated from n = 2 
chromatographic experiments.
Table 2. DLS measurements of a selective set of murine hybridoma mAb
mAb # Radius (nm) % Polydispersity % Monomer by mass
62 5.5 17 100
63 5.2 14 100
65 5.1 13 100
66 5.3 13 100
67 5.4 11 99
68 5.3 12 100
71 5.5 19 100
75 4.7 7 98
76 4.7 10 97
79 4.8 10 100
80 5.1 16 100
85 5.0 13 100
89 4.7 20 100
90 4.7 7 100
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from this treatment were used in the CIC analysis and the MALDI-
TOF-MS analysis.
MALDI-TOF-MS analysis. MALDI-TOF-MS data of the gly-
cosylated and deglycosylated mAb samples were acquired using a 
Voyager DE instrument from Applied BioSystems (Foster City, 
CA). The instrument was externally calibrated with a protein cali-
bration kit (Sigma).
Isoelectric focusing. Isoelectric-focusing (IEF) gel electro-
phoresis was performed using Novex Pre-Cast Vertical pH 3–10 
IEF Gels (Invitrogen). Antibodies were loaded at 5 μg each.   
The detailed procedures were conducted according to the manufac-
turer’s protocol. The pI of each antibody listed is the mid-point of 
the multiple bands observed on the gel due to charge heterogeneity 
introduced by the variability of the N-linked glycosylation.
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In search of an antibody that can serve as a negative control, 
we tested a low solubility human antibody CNTO607 11 on the 
murine IgG-coupled column. We found that it showed delayed elu-
tion time although not as pronounced as it did on a human IgG-
coupled column (k’ = 0.3–0.4 on murine IgG column; k' = 1.4 on 
human IgG column). Due to the absence of a low solubility murine 
antibody, we included this human mAb in our chromatography 
experiments as a negative control (data not shown).
Dynamic light scattering experiments. Particle sizes and distri-
butions of samples were determined on a DynaPro Plate Reader 
DLS instrument (Wyatt Technologies Corporation) at 20°C and 
1 mg/mL. Measurements were made using a Corning® 384-well 
black plate with clear flat bottom polystyrene (CLS3540) and   
40 μL sample in each well. For every measurement, 20 runs were 
performed. The refractive index of 1.333 at 589 nm for PBS   
buffer at 20°C was used (a standard value embedded in the soft-
ware by the manufacturer). The method of cumulants was used to 
analyze the data. When a distribution of size is present, the effective 
radius is obtained by averaging the mass-weighted radii.
Degylcosylation experiments. The deglycosylation of the mAbs 
under non-denaturing condition was accomplished by treating the 
mAbs with PNGase F (New England BioLabs, Cat #P0705L) in 20 
mM TRIS-HCl buffer, pH 7.0 at 37°C for 24 h. Mabs resulting 
Figure 2. Comparison of MALDI-toF-MS spectra before and after deglycosylation. (A) intact mAb 17 and (B) deglycosylated mAb 17; (C) intact mAb 3 
and (D) deglycosylated mAb 3. +1 is singly charged molecular ion, +2 is doubly charged molecular ion, +3 is triply charged molecular ion and LC is free 
light chain.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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